The Role of Immunohistochemistry in Rhabdomyosarcoma Diagnosis Using Tissue Microarray Technology and a Xenograft Model

REFERENCES

• Wachtel M, Runge T, Leuschner I, et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 2006;24:816–822.
   PubMed Web of Science ®Google Scholar
• Grass B, Wachtel M, Behnke S, et al. Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics. Histopathology 2009;54:873–879.
   PubMed Web of Science ®Google Scholar
• Weiss AR, Lyden ER, Anderson JR, et al. Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. J Clin Oncol 2013;31:3226–2332.
   PubMed Web of Science ®Google Scholar
• Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol 2013;20:387–397.
   PubMed Web of Science ®Google Scholar
• Rudzinski ER, Anderson JR, Lyden ER, et al. Myogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group. Am J Surg Pathol 2014;38:654–659.
   PubMed Web of Science ®Google Scholar
• Davicioni E, Anderson MJ, Finckenstein FG, et al. Molecular classification of rhabdomyosarcoma–genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol 2009;174:550–564.
   PubMed Web of Science ®Google Scholar
• Heerema-McKenney A, Wijnaendts LC, Pulliam JF, et al. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype. Am J Surg Pathol 2008;32:1513–1522.
   PubMed Web of Science ®Google Scholar
• Morotti RA, Nicol KK, Parham DM, et al. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol 2006;30:962–968.
   PubMed Web of Science ®Google Scholar
• Cessna MH, Zhou H, Perkins SL, et al. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol 2001;25:1150–1157.
   PubMed Web of Science ®Google Scholar
• Morgenstern DA, Rees H, Sebire NJ, et al. Rhabdomyosarcoma subtyping by immunohistochemical assessment of myogenin: tissue array study and review of the literature. Pathol Oncol Res 2008;14:233–238.
   PubMed Web of Science ®Google Scholar
• Zin A, Bertorelle R, Dall'Igna P, et al. Epithelioid rhabdomyosarcoma: a clinicopathologic and molecular study. Am J Surg Pathol 2014;38:273–278.
   PubMed Web of Science ®Google Scholar
• Rudzinski ER, Teot LA, Anderson JR, et al. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Am J Clin Pathol 2013;140:82–90.
   PubMed Web of Science ®Google Scholar
• Skapek SX, Anderson J, Barr FG, et al. PAX-FOXO1 fusion status drives unfavourable outcome for children with rhabdomyosarcoma: a children's oncology group report. Pediatr Blood Cancer 2013;60:1411–1417.
   PubMed Web of Science ®Google Scholar
• Parham DM, Alaggio R, Coffin CM. Myogenic tumors in children and adolescents. Pediatr Dev Pathol 2012;15:211–238.
   PubMed Web of Science ®Google Scholar
• Parham DM, Qualman SJ, Teot L, et al. Correlation between histology and PAX/FKHR fusion status in alveolarrhabdomyosarcoma: a report from the Children's Oncology Group. Am J Surg Pathol 2007;31:895–901.
   PubMed Web of Science ®Google Scholar
• Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med 2006;130:1454–1465.
   PubMed Web of Science ®Google Scholar
• Stanta G, Bonin S, Machado I, Llombart-Bosch A. Models of biobanking and tissue preservation: RNA quality in archival samples in pathology laboratories and “in vivo biobanking” by tumor xenografts in nude mice-two models of quality assurance in pathology. Biopreserv Biobank 2011;9:149–155.
   PubMed Web of Science ®Google Scholar
• Mayordomo E, Machado I, Giner F, et al. A tissue microarray study of osteosarcoma: histopathologic and immunohistochemical validation of xenotransplanted tumors as preclinical models. Appl Immunohistochem Mol Morphol 2010;18:453–461.
   PubMedGoogle Scholar
• Kashima K, Watanabe M, Sato Y, et al. Inhibition of metastasis of rhabdomyosarcoma by a novel neutralizing antibody to CXC chemokine receptor-4. Cancer Sci 2014;105:1343–50.
   Google Scholar
• Bergantin E, Quarta C, Nanni C, et al. Sulforaphane induces apoptosis in rhabdomyosarcoma and restores TRAIL-sensitivity in the aggressive alveolar subtype leading to tumor elimination in mice. Cancer Biol Ther 2014;15:1219–1225.
   PubMed Web of Science ®Google Scholar
• Huang HJ, Liu J, Hua H, et al. MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis. Oncotarget 2014;5:2161–2175.
   PubMedGoogle Scholar
• Stebbing J, Paz K, Schwartz GK, et al. Patient-derived xenografts for individualized care in advanced sarcoma. Cancer 2014;120:2006–2015.
   PubMed Web of Science ®Google Scholar
• Monsma DJ, Cherba DM, Richardson PJ, et al. Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance. Pediatr Blood Cancer 2014;61:1570–1577.
   PubMed Web of Science ®Google Scholar
• Hinson AR, Jones R, Crose LE, et al. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Front Oncol 2013;17:183.
   Google Scholar
• Sana J, Zambo I, Skoda J, et al. CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas andrhabdomyosarcoma cell lines. Anal Cell Pathol (Amst) 2011;34:303–318.
   PubMed Web of Science ®Google Scholar
• Seitz G, Pfeiffer M, Fuchs J, et al. Establishment of a rhabdomyosarcoma xenograft model in human-adapted mice. Oncol Rep 2010;24:1067–1072.
   PubMed Web of Science ®Google Scholar
• Soffer SZ, Kim E, Huang J, et al. Resistance of a VEGF-producing tumor to anti-VEGF antibody: unimpeded growth of human rhabdoid tumor xenografts. J Pediatr Surg 2002;37:528–532.
   PubMed Web of Science ®Google Scholar
• Gansler T, Gerald W, Anderson G, et al. Characterization of a cell line derived from rhabdoid tumor of kidney. Hum Pathol 1991;22:259–266.
   PubMed Web of Science ®Google Scholar
• Mosakhani N, Guled M, Leen G, et al. An integrated analysis of miRNA and gene copy numbers in xenografts of Ewing's sarcoma. J Exp Clin Cancer Res 2012;20:24.
   Web of Science ®Google Scholar
• Kresse SH, Meza-Zepeda LA, Machado I, et al. Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations. Cancer 2012;118:558–570.
   PubMed Web of Science ®Google Scholar